3児の親さん薬剤師のブログ

とある薬剤師です。感染症治療を考える素材をちょこっと提供。noteもあります https://note.com/twin1980

Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ß-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis

OFIDに報告された、腸内細菌による菌血症に対するステップダウンとしての、経口キノロン or ST vs ß-lactams のメタアナ。

 

academic.oup.com

 

まとめ・感想

 

BL’sはFQと比べて、死亡率に差はないけど、再発多いかもよ。

でもでも、BL’sはPK/PD的にいまいちな研究が多かったよ。

 

これって、PK/PDを最適化すれば、再発率どうなるのなかな?

むしろ、死亡率変わらない点から、PK/PDのインパクトは少ないのかな?

 

って感じてしまうレトロを集めたメタアナ。

 

  • 8 retrospective studies : 2,289 patients.
  • All-cause mortality : FQ/TMP-SMX or BL’s (OR 1.13; 95%CI, 0.69–1.87).
  • Overall recurrence of infection :  BL’s vs. FQ’s (OR 2.05, 95% CI 1.17 to 3.61).
  • limited to recurrent bacteremia :  BL’s vs. FQ’s (OR 2.32, 95% CI 0.99 to 5.44).

 

Abstract


Background

Using published data, we sought to compare outcomes in patients transitioned to either oral fluoroquinolones (FQ) or trimethoprim-sulfamethoxazole (TMP-SMX) versus ß-lactams (BL’s) after an initial intravenous (IV) course for gram-negative rod (GNR) bacteremia.

Methods

We conducted a systematic review of PubMed and EMBASE and published IDWeek abstracts. We included studies that reported all-cause mortality and/or infection recurrence in patients transitioned to oral FQ/TMP-SMX and BL’s.

Results

Eight retrospective studies met inclusion criteria with data for 2,289 patients, of whom 65% were transitioned to oral FQ, 7.7% to TMP-SMX, and 27.2% to BL’s. Follow up periods ranged from 21 to 90 days. All-cause mortality was not significantly different between patients transitioned to either FQ/TMP-SMX or BL’s (OR 1.13; 95%CI, 0.69–1.87). Overall recurrence of infection, either bacteremia or the primary site, occurred more frequently in patients transitioned to oral BL’s vs. FQ’s (OR 2.05, 95% CI 1.17 to 3.61). Analysis limited to recurrent bacteremia was similarly suggestive although limited by small numbers (OR 2.32, 95% CI 0.99 to 5.44). However, based on known pharmacokinetics/pharmacodynamics, prescribed ß-lactam dosing regimens were frequently suboptimal.

Conclusions

In the step-down IV to oral treatment of GNR bacteremia, we found insufficient data regarding outcomes after oral TMP-SMX; however, selection of a FQ over commonly utilized ß-lactam regimens may reduce chances of infection recurrence. While this may be a class effect, it may simply be the result of inadequate dosing of ß-lactams. Additional investigations are warranted to determine outcomes with TMP-SMX and optimized oral ß-lactam dosing regimens.

 

f:id:akinohanayuki:20190816054105p:plain

f:id:akinohanayuki:20190816054117p:plain

 

日本語版 サンフォード感染症治療ガイド2019(第49版)

日本語版 サンフォード感染症治療ガイド2019(第49版)

  • 作者: 菊池賢,橋本正良,M.D. David N. Gilbert,M.D. Henry F.Chambers,M.D. George M. Eliopoulos,M.D. Michael S. Saag,M.D. Andrew T. Pavia
  • 出版社/メーカー: ライフサイエンス出版
  • 発売日: 2019/07/07
  • メディア: 単行本
  • この商品を含むブログを見る